Lower Health Care Premiums for All Americans Act — HR-6703 (R-IA) · Congress.wiki

Lower Health Care Premiums for All Americans Act — HR-6703 (R-IA) · Congress.wiki

Pros & Cons

The bill increases PBM and drug‑price transparency and expands options for small employers, potentially lowering drug costs and broadening benefits access, but it also imposes sizable compliance and privacy burdens, risks market disruptions and reduced state consumer protections, and contains policy constraints (including on abortion coverage) that may narrow options for vulnerable enrollees.

Potential Benefits

6

Millions of plan sponsors, employers, and enrollees: standardized, machine‑readable PBM and drug‑level reporting (NDC-level spending, rebates, PBM compensation) increases transparency and gives purchasers and regulators data to negotiate lower drug costs and design cost-saving reforms.
Economy
middle-class-families, plan-sponsors, employers, taxpayers, hospitals-health-systems
Patients (especially those with chronic conditions) can request summary and claims‑level 'difference' data showing what the plan paid versus the pharmacy was paid, improving individuals' understanding of out-of-pocket costs and enabling better personal advocacy.
Civil Rights
patients-chronic-conditions, middle-class-families
Disclosure of PBM payments to brokers/consultants and affiliated‑pharmacy dispensing rates increases visibility into conflicts of interest and anti‑competitive practices, helping plan sponsors and regulators detect and correct pricing drivers.
Government
plan-sponsors, state-governments, taxpayers

Potential Drawbacks

7

Plans, PBMs, and vendors (particularly smaller entities) face substantial compliance costs and legal exposure from detailed machine‑readable reporting obligations plus high civil monetary penalties, costs that are likely to be passed on to consumers as higher premiums or reduced plan offerings.
Economy
small-business-owners, middle-class-families, taxpayers, hospitals-health-systems
Participant‑level and claims‑level disclosures increase privacy and re‑identification risk and impose heavy HIPAA/HITECH compliance burdens on plans, creating the possibility of inadvertent exposure of sensitive health information.
Civil Rights
patients-chronic-conditions, participants-beneficiaries
Enforcement and disclosure requirements may prompt PBMs or affiliated pharmacies to change business practices, restrict services, or exit markets, which could disrupt access to drugs and reduce choice for beneficiaries, including Medicaid and other vulnerable populations.
Health & Safety
patients-chronic-conditions, medicaid-beneficiaries

Based on analysis of 5 sections of legislative text.

Bill Summary

Summary

Creates new federal rules to expand and regulate employer-based and association health coverage, allow certain employer-funded reimbursement arrangements that pair with individual market or Medicare coverage, and require extensive pharmacy benefit manager (PBM) transparency and reporting to group health plans. It also amends tax and ERISA rules (including W-2 reporting and cafeteria plan treatment) and provides open-ended funding for cost-sharing reduction (CSR) payments with a restriction on using those funds for most abortion coverage. Requires Treasury, HHS, and Labor to issue implementing regulations and standard report formats, sets privacy limits consistent with HIPAA, and authorizes civil monetary penalties for failures or false reporting. Key effective dates: CHOICE HRA and tax/ERISA tax reporting rules apply for plan/tax years beginning after Dec 31, 2025; PBM and ERISA reporting provisions take effect for plan years beginning 30 months after enactment, with certain rulemaking required within 18 months.

Key Points

Click to see evidence